Full financial disclosures and author roles may be found in the online version of this article.
Version of Record online: 13 OCT 2011
Copyright © 2011 Movement Disorder Society
Volume 27, Issue 1, pages 31–41, January 2012
How to Cite
Venuto, C. S., McGarry, A., Ma, Q. and Kieburtz, K. (2012), Pharmacologic approaches to the treatment of Huntington's disease. Mov. Disord., 27: 31–41. doi: 10.1002/mds.23953
Relevant conflicts of interest/financial disclosures: Authors Venuto, McGarry, and Kieburtz receive research support from a contract between the University of Rochester and NeuroSearch. Author Kieburtz also receives research support from Medivation, Inc.
- Issue online: 13 JAN 2012
- Version of Record online: 13 OCT 2011
- Manuscript Accepted: 14 AUG 2011
- Manuscript Revised: 29 JUL 2011
- Manuscript Received: 23 MAY 2011
Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation. © 2011 Movement Disorder Society